New York – Paul Hastings LLP, a leading global law firm, announced today that the firm advised Merck, known as MSD outside the United States and Canada, in a strategic collaboration with Amathus Therapeutics to develop novel small molecule therapeutic candidates for neurodegenerative diseases.

Under the terms of the agreement, Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery, and will be eligible for milestone payments from Merck in excess of $500 million per program associated with the successful development of candidates.

The Paul Hastings team was led by M&A partners David Shine and Samuel Waxman and included partner Eric Keller and associates Jordan Goldman and Bo-Shan Xiang.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.